CD20 and Its Antibodies: Past, Present, and Future

The pan B-cell marker CD20 was cloned more than 3 decades ago. It has been intensively studied ever since, allowing the specific identification and targeting of B cells facilitating the development of antibody-mediated immunotherapy. In this review, we document the current understanding of how CD20 regulates B-cell biology. We also describe the emerging knowledge of how anti-CD20 antibodies elicit their therapeutic responses, revealing how this has changed and matured throughout the decades of their use.